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Objectives The primary objective of this study was to elucidate mechanisms underlying the link between vitamin D status
and cardiovascular disease by exploring the relationship between 25-hydroxyvitamin D (25-OH D), an established
marker of vitamin D status, and vascular function in healthy adults.
Background Mechanisms underlying vitamin D deficiency-mediated increased risk of cardiovascular disease remain un-
known. Vitamin D influences endothelial and smooth muscle cell function, mediates inflammation, and modu-
lates the renin-angiotensin-aldosterone axis. We investigated the relationship between vitamin D status and vas-
cular function in humans, with the hypothesis that vitamin D insufficiency will be associated with increased
arterial stiffness and abnormal vascular function.
Methods We measured serum 25-OH D in 554 subjects. Endothelial function was assessed as brachial artery flow-
mediated dilation, and microvascular function was assessed as digital reactive hyperemia index. Carotid-femoral
pulse wave velocity and radial tonometry-derived central augmentation index and subendocardial viability ratio
were measured to assess arterial stiffness.
Results Mean 25-OH D was 31.8  14 ng/ml. After adjustment for age, sex, race, body mass index, total cholesterol,
low-density lipoprotein, triglycerides, C-reactive protein, and medication use, 25-OH D remained independently
associated with flow-mediated vasodilation (  0.1, p  0.03), reactive hyperemia index (  0.23, p 
0.001), pulse wave velocity (  0.09, p  0.04), augmentation index (  0.11, p  0.03), and subendo-
cardial viability ratio (  0.18, p  0.001). In 42 subjects with vitamin D insufficiency, normalization of 25-OH
D at 6 months was associated with increases in reactive hyperemia index (0.38  0.14, p  0.009) and subendocar-
dial viability ratio (7.7  3.1, p  0.04), and a decrease in mean arterial pressure (4.6  2.3 mm Hg, p  0.02).
Conclusions Vitamin D insufficiency is associated with increased arterial stiffness and endothelial dysfunction in the conduc-
tance and resistance blood vessels in humans, irrespective of traditional risk burden. Our findings provide impe-
tus for larger trials to assess the effects of vitamin D therapy in cardiovascular disease. (J Am Coll Cardiol
2011;58:186–92) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.051Vitamin D deficiency is a highly prevalent condition affect-
ing 30% to 50% of the U.S. population and is associated
with hypertension, insulin resistance, and left ventricular
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2011, accepted February 15, 2011.hypertrophy (1,2). More recently, vitamin D deficiency has
been implicated as a risk factor for cardiovascular disease
and overall mortality in the general population (3,4). Al-
though the link between the traditional role of vitamin D in
bone and calcium metabolism has been extensively studied,
the mechanisms by which vitamin D deficiency confers
vascular risk remain unexplained.
Vitamin D receptors and 1-alpha-hydroxylase, which
converts vitamin D into the hormonal 1,25-dihydroxyvitamin D
form, are present in many tissues including endothelial cells
(5). Endothelial cell vitamin D receptors are up-regulated
under stress, and its binding with the hormonal vitamin D
ligand modulates response elements in the vascular endo-
thelial growth factor promoter (6). Vitamin D also affects
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July 5, 2011:186–92 Vitamin D Status and Vascular Functionthe vascular wall by regulating the renin-angiotensin-aldosterone
axis and exerts anti-proliferative effects on vascular smooth
muscle (7). Moreover, vitamin D plays a crucial role in
immune modulation by regulating lymphocyte and monocyte/
macrophage differentiation and release of inflammatory cy-
tokines. This in turn might determine monocyte infiltration
and cholesterol retention in the vascular wall (8,9).
It is well established that vascular endothelial dysfunction
and arterial stiffness precede and contribute to the devel-
opment of cardiovascular disease and are both predictors
of long-term morbidity and mortality (10,11). We inves-
tigated the mechanisms underlying the link between
vitamin D insufficiency and cardiovascular disease by ex-
ploring the relationship between 25-hydroxyvitamin D
(25-OH D), an established marker of vitamin D status, and
vascular function. Our hypothesis was that vitamin D
insufficiency will be associated with increased arterial stiff-
ness and abnormal vascular function.
Methods
Subjects. A total of 554 healthy participants, 20 to 79 years
f age, were recruited by advertisement or by invitation to
mployees of Emory University and Georgia Institute of
echnology, as part of the Emory Predictive Health Initia-
ive. Subjects were free of any acute illness and had normal
erformance status. Hypertension, hypercholesterolemia,
nd diabetes mellitus were defined according to the Seventh
eport of the Joint National Committee on the Prevention,
etection, Evaluation, and Treatment of High Blood Pres-
ure; Adult Treatment Panel III; and American Diabetes
ssociation criteria, respectively (12–14). Vascular testing
nd blood draws were performed after an overnight fast.
inety-one subjects with serum 25-OH D levels 30
ng/ml at baseline testing had repeat measurements per-
formed after 6 months. The study was approved by the
Emory University Institutional Review Committee. In-
formed consent was obtained from all subjects.
Laboratory tests. Blood samples were obtained for a lipid
profile, and metabolic panel, urine albumin/creatinine ratio,
high-sensitivity C-reactive protein (CRP), and serum
25-OH D levels (liquid chromatography and tandem mass
spectrometry) were measured by commercially available
assays (Quest Diagnostics, Madison, New Jersey). The
detection limit for the 25-OH D was 4 ng/ml, with a
previously reported inter-assay variation coefficient of ap-
proximately 10% (15).
Arterial stiffness testing. After an initial rest period of 10
min with subjects in a supine position in a quiet,
temperature-controlled room, blood pressure was measured
3 times at 5-min intervals by an automatic device (Omron,
Kyoto, Japan) from the dominant arm and documented as
the mean value of the final 2 measurements.
Pulse wave velocity (PWV), augmentation index (AIX),
and subendocardial viability ratio (SEVR) were derived with
the Sphygmocor device (Atcor Medical, Sydney, Australia),as previously described (16).
Briefly, the setup consists of a
handheld tonometer attached to
a device and a laptop computer.
High-fidelity sequential pressure
waveforms are obtained by plac-
ing the tonometer on the radial
artery of the dominant wrist. The
device then applies a transfer
function to these peripheral mea-
surements to estimate central
(aortic) pressure parameters and
the degree of pressure augmenta-
tion secondary to reflected waves
from the periphery. This permits
derivation of an AIX (augmented pressure/total central
pulse pressure) and SEVR (area under diastolic phase/
systolic phase), which are considered complex and compos-
ite markers of wave reflections and arterial stiffening. Due to
its sensitivity to heart rate, a standardized value to 75
beats/min is calculated and used for AIX for the purpose of
this study.
The PWV was determined by acquiring waveforms at
the carotid and femoral arterial sites with electrocardio-
gram gating. Velocity (distance/time in m/s) was calcu-
lated by measuring the time interval between electrocar-
diogram R-wave and the recorded waveforms at each site,
whereas distance between sites was measured manually.
Quality control indexes were evaluated at the time of
study and nonacceptable readings discarded and repeated.
Reproducibility studies in our laboratory on 9 subjects on
consecutive days have demonstrated a coefficient of vari-
ation of 3.8%, 13.8%, and 20.3% for PWV, SEVR, and
AIX, respectively.
Flow-mediated dilation. Endothelium-dependent bra-
chial artery flow-mediated dilation (FMD) was measured to
evaluate endothelium-dependent vascular function. The
detailed methodology for performing this test has been
described previously (17). In our laboratory, the mean
difference in FMD between assessments performed in 11
subjects on consecutive days was 1.26  0.76%, with a
correlation coefficient of 0.75. The mean difference in the
FMD between 2 readings of the same 11 measurements was
0.82  0.48% (r  0.97).
Pulsatile arterial tonometry. During the FMD testing
described in the preceding text, digital vascular function was
also assessed simultaneously as fingertip reactive hyperemia
(Endo-PAT2000, Itamar Medical, Caesarea, Israel) as de-
scribed previously (18). Briefly, pneumatic plethysmographs
apply uniform pressure at both index fingers that allows for
measurement of minute, pulsatile volume changes, generat-
ing a pulse wave tracing. Reactive hyperemia index (RHI) is
defined as the ratio of post-deflation to baseline pulse
amplitude in the hyperemic finger divided by that in the
Abbreviations
and Acronyms
25-OH D  25-
hydroxyvitamin D
AIX  augmentation index
CRP  C-reactive protein
FMD  (brachial artery)
flow-mediated dilation
PWV  pulse wave velocity
RHI  reactive hyperemia
index
SEVR  subendocardial
viability ratiocontra-lateral finger.
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Vitamin D Status and Vascular Function July 5, 2011:186–92Statistical considerations. Study variables are described as
the mean  SD (unless otherwise specified) for continuous
variables or as counts or proportions for categorical vari-
ables. Age, body mass index, 25-OH D level, CRP, lipid
profile, FMD, RHI, PWV, AIX, and SEVR values were
treated as continuous variables. Diagnosed hypertension,
hypercholesterolemia, diabetes mellitus, smoking, sex, med-
ication use (anti-hypertensive drugs, lipid or glucose lower-
ing agents), and vitamin D supplementation (10 g/day)
were categorical variables. Continuous variables were tested
for normality with the Kolmogorov-Smirnov criterion.
Skewed variables were log transformed and tested again for
normality before any parametric analysis.
Univariate correlations between serum 25-OH D con-
centrations and measured parameters were performed with
Pearson’s correlation. Multivariate linear regression models
were constructed to determine relationships between vita-
min D status and vascular function parameters before and
after adjustment for age, sex, race, body mass index, total
cholesterol, low-density lipoprotein, triglycerides, CRP, and
medication use. Group differences were evaluated by Stu-
dent t tests or 1-way analysis of variance.
For follow-up analysis, participants with vitamin D in-
sufficiency at baseline (n  91) were divided into those who
normalized their 25-OH D 30 ng/ml levels and those
who remained insufficient (25-OH 30 ng/ml) after
Figure 1 Relationship Between Serum 25-OH D, Arterial Stiffne
25-OH D  25-hydroxyvitamin D (ng/ml); AIX  augmentation index; FMD  brach
PWV  pulse wave velocity (m/s); RHI  reactive hyperemia index; SEVR  subenmonths. We compared average changes in mean arterial
ressure, FMD, RHI, PWV, AIX, and SEVR (baseline –
-month value) between groups with unpaired samples
tests. Paired samples t tests were performed for comparison
f within-group differences. Data are presented as mean SD
in the text and as specified in the legends of Figures 1, 2, and 3.
tatistical significance was based on 2-tailed tests, and
values 0.05 were considered significant. Analyses were
erformed with SPSS (version 17.0, SPSS, Inc., Chicago,
llinois).
esults
aseline characteristics of the 554 subjects are shown in
able 1. Mean 25-OH D level was 31.8 ng/ml (range 4 to
6 ng/ml), and 47% of subjects had insufficient 25-OH D
evels (30 ng/ml).
elationship between vitamin D status and subject char-
cteristics. Serum 25-OH D correlated with body mass
ndex (r  0.23, p  0.001) and high-density lipoprotein
evels (r 0.2, p 0.001). Among the categorical variables,
5-OH D was significantly lower in women, African
mericans, Hispanics, and those with hypertension or
iabetes (Table 2). Subjects taking regular vitamin D
upplementation had higher 25-OH D levels (38 ng/ml vs.
nd Vascular Function
ry flow mediated dilation (%); MAP  mean arterial pressure (mm Hg);
dial viability ratio. p values are for 2-tailed test of significance.ss, a
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July 5, 2011:186–92 Vitamin D Status and Vascular Function29 ng/ml, p  0.001) and were significantly older (54 years
s. 46 years, p  0.001). When the 544 subjects were
ivided on the basis of risk factor burden into groups with
one, 1, or 2 or more risk factors, a stepwise decline in mean
5-OH D levels was observed with increasing risk factor
urden (p analysis of variance  0.012) (Fig. 2).
Figure 2 Cardiovascular Risk Burden
and Levels of Serum 25-OH D
Risk factors included: age (men older than 55 or women older than 65 years),
presence of diabetes mellitus, hypertension, hypercholesterolemia, or smoking
history. Box plots: the middle band represents median, bottom and top of the
box represent lower and upper quartiles, and end of whiskers represent high-
est and lowest values that are not outliers. p value for 1-way analysis of vari-
ance. n  266, 128, and 150 for groups with 0, 1, or 2 risk factors,
respectively. 25-OH D  25-hydroxyvitamin D.
Figure 3 Follow-Up Measurements in Subjects With Vitamin D
Mean arterial pressure, reactive hyperemia index, and subendocardial viability rati
30 ng/ml) after 6 months (top panels), and those in whom vitamin D levels nor
*Significant between and within-group differences.Relationship between vitamin D status and arterial stiffness.
Lower levels of 25-OH D were associated with abnormal-
ities in the indexes of arterial stiffness with higher AIX and
PWV and lower SEVR (Fig. 1). After multivariate adjust-
ment for age, sex, race, body mass index, total cholesterol,
low-density lipoprotein, triglycerides, C-reactive protein,
and medication use, 25-OH D remained independently
associated with PWV (adjusted R2 0.32, 0.09, p
.04), AIX (adjusted R2 0.42, 0.11, p 0.03), and
EVR (adjusted R2  0.16,   0.18, p  0.001).
Relationship between vitamin D status and vascular
function. Lower levels of 25-OH D were associated with
abnormalities in the indexes of vascular function with lower
FMD and RHI (Fig. 1). Moreover, 25-OH D levels had an
independent association with FMD (adjusted R2  0.11,
 0.1, p 0.03) and RHI (adjusted R2 0.09,  0.23,
p  0.001) in multivariate analysis adjusting for the afore-
mentioned variables.
In age-, sex-, and race-adjusted analyses, no significant
correlation existed between log CRP and 25-OH D.
Subgroup analysis in subjects free of cardiovascular risk
factors. A secondary analysis was performed in a subgroup
of 233 “healthy” subjects with absence of traditional cardio-
vascular risk factors, to explore the association between
levels of 25-OH D and vascular function independent of the
confounding effects of risk factors and vitamin D intake.
After multivariate adjustment for age, sex, race, body mass
index, systolic arterial pressure, and total cholesterol/high-
density lipoprotein ratio, 25-OH D levels remained inde-
ficiency
seline and after 6 months in 49 subjects who remained insufficient (25-OH D
d after 6 months (n  42, bottom panels). Error bars represent standard error.Insuf
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Vitamin D Status and Vascular Function July 5, 2011:186–92pendently associated with AIX (adjusted R2  0.44,  
0.02, p  0.001), PWV (adjusted R2  0.2,   0.02,
 0.005), FMD (adjusted R2  0.12,   0.01, p 
0.04), and RHI (adjusted R2  0.07,   0.02, p  0.003)
n this cohort but accounted for small changes in variability.
ollow-up. Of the 91 participants with vitamin D insuffi-
iency, 42 had normalized vitamin D status (25-OH D30
g/ml) and 49 subjects remained in insufficient status after
months. Subjects who normalized their 25-OH D levels
ad significant increases in RHI (0.38  0.29, p  0.009)
nd SEVR (7.7  11.4, p  0.04) and a decrease in mean
rterial pressure (4.6  5.6 mm Hg, p  0.02). These
differences were significantly greater when compared with
subjects where 25-OH D levels remained in the insufficient
range (0.38  0.29 vs. 0.07  0.33, p  0.01; 7.7  11.4
vs. 1.1  9.5, p  0.03; 4.6  5.6 mm Hg vs. 0.9 
.7 mm Hg, p  0.02, for RHI, SEVR, and mean arterial
ressure, respectively) (Fig. 3). Thus, subjects with corrected
itamin D insufficiency had improved microvascular vaso-
ilation and arterial stiffness.
iscussion
n a study that comprehensively assesses vascular function in
community-based asymptomatic population, we demon-
trated an association between vitamin D status and several
ndexes of vascular health, including arterial stiffness and
ndothelial function. We studied a large multiethnic pop-
lation over a wide age range but with a relatively low risk
actor burden, and we employed multiple established mo-
alities to assess subclinical vascular dysfunction. Increased
rterial stiffness—assessed by measurements of PWV, AIX,
nd SEVR—was associated with lower 25-OH D levels. In
ddition, lower 25-OH D levels were associated with worse
Demographic CharacteristicsTable 1 Demographic Characteristics
Age (yrs) 47 13
Men 45
Caucasian 71
African American 22
Hispanic 2
Body mass index (kg/m2) 26 5
Diabetes 5
Hypertension 19
Hypercholesterolemia 25
Smoking 3
25-hydroxyvitamin D (ng/ml) 32 14
Calcium (mg/dl) 9.4 0.3
Cholesterol/high-density lipoprotein 3.1 0.9
Triglycerides (mg/dl) 94 46
hs-CRP (mg/dl) 0.6 0.8
Statin use 25
Vitamin D supplements 32
Framingham Risk Score 2.7 6.2
Values are mean  SD or %.
CRP  C-reactive protein.ascular endothelial function, assessed in the conductanceessels with FMD and in the microvasculature with pulsatile
igital arterial tonometry. Moreover, subgroup analysis
erformed in selected individuals free of all vascular risk
actors in order to exclude the confounding effects of risk
actors on vascular function also revealed an independent
ssociation between vitamin D status and vascular function.
hese observations are consistent with the well-established
ssociations between vitamin D deficiency and a broad
ange of cardiovascular disorders and risk factors (1,3).
25-hydroxyvitamin D (25-OH D) is considered to be the
est indicator of vitamin D status in those with normal
idney function and reflects the level of circulating substrate
or the tightly regulated hydroxylation into the active,
ormonal form of vitamin D (1,25-OH2 D) (1). Alterna-
ively, measurement of 1,25-OH2 D is performed in chronic
kidney disease, as decreases in renal 1--hydroxylase activity
often result in low 1,25-OH2 D levels and hypocalcemia.
Previous small studies have also shown increased AIX
and lower FMD in hemodialysis patients with lower levels
of 1,25-OH2 D, but our findings in a community-based
population are novel (19,20). In hypertensive patients, levels of
25-OH D were inversely associated with plethysmography-
derived calf vascular resistance (21), and the third National
Health and Nutrition Examination Survey found increased
pulse pressure, a nonspecific marker of arterial compliance,
with vitamin D deficiency (22). Finally, few well-designed
interventional trials have explored whether vascular function
can be improved by vitamin D supplementation (23,24).
In experimental studies vitamin D modulates endothelial
cell function by decreasing expression of adhesion mole-
cules, providing protection against advanced glycation prod-
ucts, by reduction in endothelium-dependent contractions
and modulation of calcium influx (25–27). Vitamin D
Relationship Between Vitamin D Statusand Subject CharacteristicsTable 2 Rel tionship Between Vitamin D Statusand Subject Characteristics
ng/ml p Value
Sex
Men 34 14 0.03
Women 31 13
Race
Caucasian 35 14 0.001
African American 23 12
Diabetes
Yes 22 8 0.001
No 32 14
Hypertension
Yes 26 15 0.006
No 34 13
Hyperlipidemia
Yes 32 14 NS
No 32 14
Vitamin D supplement
Yes 38 12 0.001
No 29 14Values are mean  SD serum 25-hydroxyvitamin D concentration. p values were derived from the
Student independent samples t test.
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July 5, 2011:186–92 Vitamin D Status and Vascular Functiondeficiency also activates the renin-angiotensin-aldosterone
system, causes proliferation of vascular smooth muscle cells,
activates macrophage invasion of the vascular wall, promotes
calcification, and increases parathyroid hormone release,
effects that are ameliorated by vitamin D supplementation
(7,25,28). Finally, vitamin D might modulate adaptive
immunity by reducing inflammatory cytokine gene expres-
sion, alternating circulating subsets of T-cells, and reducing
inflammation (29,30). In clinical studies, an increased inci-
dence of adverse cardiovascular events has been found in the
Framingham cohort with decreased serum 25-OH D, and
community-based studies have observed associations be-
tween vitamin D deficiency and cardiovascular disease and
its risk factors, as in our population (3,4).
Our findings of increased arterial stiffness and endothelial
dysfunction with low 25-OH D provide mechanistic expla-
nation of how depressed vitamin D status, by precipitating
vascular dysfunction, might predispose individuals to a
higher risk for the development of cardiovascular disease
and adverse events. Brachial artery FMD, a measure of
endothelial function and nitric oxide bioavailability, is also
an independent predictor of future adverse cardiovascular
events (31). Persistence of endothelial dysfunction despite
therapeutic interventions is associated with worse prognosis,
and normalization of FMD leads to improved outcomes
(32). Similarly, RHI has been negatively associated with
cardiovascular risk factors, and low RHI seems to be
associated with worse long-term outcome (33). Similarly,
arterial stiffness indexes including AIX and SEVR are
independent predictors of adverse outcomes (16,34).
Increased arterial stiffness and endothelial dysfunction are
also strong predictors for future development of hyperten-
sion (35). In this context, the majority of large cross-
sectional studies have demonstrated an inverse relationship
between 25-OH D levels and blood pressure, and the risk of
future hypertension seems to be greater in those with
vitamin D deficiency (36,37). Although interventional trials
with vitamin D supplementation in hypertension are sparse,
a study in post-menopausal women reported a 7.8-mm Hg
reduction in systolic blood pressure with vitamin D replace-
ment (38).
Our findings of higher serum 25-OH D in men com-
pared with women, Caucasians compared with African
Americans and Hispanics, and in participants taking vita-
min D have been previously reported (39). Similarly, higher
body mass index, lower high-density lipoprotein, and pres-
ence of diabetes or hypertension were associated with
decreased 25-OH D levels (1) (Table 2).
It is noteworthy that our subjects were asymptomatic and
ad normal serum calcium and urinary albumin/creatinine
atio (Table 1). In addition, all subjects had an estimated
lomerular filtration rate 60 ml/min/1.73 m2, and none
eported use of high-dose vitamin D supplements (2,000
U daily) at baseline. Although the highest 25-OH D level
as 96 ng/ml in our population, levels 240 ng/ml have
een associated with displacement of bound 1,25-OH2 Dnd subsequent hypercalcemia (40). Although vitamin D
oxicity can be serious, vitamin D supplementation normal-
zes 25-OH D levels and exerts antirachitic effects. Finally,
ovel vitamin D analogs with less calciphylactic effects need
o be investigated in cardiovascular disease.
tudy limitations. The cross-sectional, observational de-
ign of our current study precludes definitive conclusions
egarding the causal relationship between vascular dysfunc-
ion and hypovitaminosis D. Also, the magnitude of con-
ribution of hypovitaminosis D to vascular dysfunction
ight be variable and modest. However, the improvements
e observed in some of these subclinical markers of vascular
ealth with normalization of vitamin D insufficiency help
onfirm the link between vitamin D status and vascular
ealth and also highlight a potential role for vitamin D
herapy in reducing cardiovascular risk. We did not find
ignificant improvements in all measures of vascular dys-
unction in the follow-up study in those who normalized
itamin D levels. This might be because we were under-
owered to observe such a change, the study was observa-
ional, and the supplementation was variable. However,
itamin D supplementation seems to significantly improve
ascular function (23,24).
It is also possible that other subject characteristics such as
hysical activity might account for the associations we
bserved. Increased physical activity is known to improve
ascular function and might also improve vitamin D status
y increasing sunlight exposure. We previously demon-
trated an independent correlation between vitamin D status
nd cardiovascular fitness, measured by cardiopulmonary
xercise testing (41).
onclusions
itamin D insufficiency is associated with increased arterial
tiffness and endothelial dysfunction in the conductance and
esistance blood vessels in humans, irrespective of tradi-
ional risk factor burden. Normalization of vitamin D status
n insufficient individuals is associated with improvements
n several parameters of vascular function. Our findings
rovide impetus for larger trials to assess the effect of
itamin D therapy on prevention of cardiovascular disease in
ndividuals with vitamin D insufficiency.
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